Gilead's Hepatitis C Drug Approved by FDA

The video discusses a new drug by Gilead that treats all six forms of hepatitis C, providing access to underserved markets. It highlights the challenges in treating genotypes 2 and 3, which previously required drug combinations with side effects. The new drug simplifies treatment and is priced at $74,000 for 12 weeks, which is lower than expected. Gilead's strategy involves competitive pricing and securing market share before competitors like Merck and AbbVie enter. The video also explores Gilead's market positioning and future strategies to maintain its lead.

What are the implications of treating hepatitis C effectively on the first attempt?

What strategies might Gilead employ to maintain its market position as competitors enter?